Shares of Bionano Genomics (NASDAQ: BNGO) surged 29.14% in after-hours trading on Wednesday following the release of its first-quarter 2025 earnings report, which exceeded analyst expectations on key metrics.
The company reported a quarterly loss of $1.15 per share, significantly beating the analyst consensus estimate of a $3.02 loss by 61.92%. This marks a substantial improvement from the $35.75 per share loss reported in the same period last year. Revenue for the quarter came in at $6.50 million, slightly above the analyst estimate of $6.23 million, though it represents a 25.88% decrease from the $8.77 million reported in Q1 2024. Bionano Genomics also highlighted a gross margin of 46% for the quarter.
Looking ahead, Bionano Genomics updated its full-year 2025 revenue outlook to a range of $26 million to $30 million, with second-quarter revenue projected between $6.3 million and $6.8 million. The company reiterated its plan to install 15 to 20 new Optical Genome Mapping (OGM) systems in 2025, signaling continued focus on expanding its technology's adoption. Additionally, Bionano reported that its cash runway has been extended into the first quarter of 2026, supported by cost-saving measures, capital efficiency, debt restructuring, and recent equity capital raises.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.